Theriva Biologics, Inc. SEC filings TOVX
Theriva Biologics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 25, 1998. Its latest annual report, Form ARS, was filed on Jun 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (material agreement, acquisition or sale of assets, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 20, 2026 | Nov 18, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 9, 2026 | Oct 9, 2026 |
| DEF 14A | Proxy statement | Jun 29, 2026 | Aug 3, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 18, 2026 | Jun 18, 2026 |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 5, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | Apr 20, 2026 |
| DEF 14A | Proxy statement | Mar 16, 2026 | Apr 9, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2026 | Mar 4, 2026 |
| DEF 14A | Proxy statement | Jan 5, 2026 | Feb 11, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2025 | Dec 23, 2025 |
| DEFA14A | Additional proxy material | Nov 12, 2025 | — |
| DEF 14A | Proxy statement | Nov 10, 2025 | Dec 15, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 31, 2025 | Dec 15, 2025 |
| DEF 14A | Proxy statement | Jul 9, 2025 | Aug 29, 2025 |
| DEF 14A | Proxy statement | Sep 30, 2024 | Oct 31, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 18, 2024 | Sep 18, 2024 |
| DEF 14A | Proxy statement | Aug 14, 2023 | Oct 2, 2023 |
| DEF 14A | Proxy statement | Aug 16, 2022 | Sep 30, 2022 |
| DEFA14A | Additional proxy material | Aug 11, 2022 | — |
| PRE 14A | Preliminary proxy statement | Aug 3, 2022 | Aug 3, 2022 |
| DEFA14A | Additional proxy material | Aug 1, 2022 | — |
| DEFA14A | Additional proxy material | Oct 6, 2021 | — |
| DEFA14A | Additional proxy material | Sep 21, 2021 | — |
| DEF 14A | Proxy statement | Aug 16, 2021 | Sep 21, 2021 |
| PRE 14A | Preliminary proxy statement | Aug 3, 2021 | Aug 9, 2021 |
| DEF 14A | Proxy statement | Aug 4, 2020 | Sep 17, 2020 |
| DEF 14A | Proxy statement | Jul 15, 2019 | Sep 5, 2019 |
| DEF 14A | Proxy statement | Aug 14, 2018 | Sep 24, 2018 |
| DEFA14A | Additional proxy material | Aug 9, 2018 | — |
| PRE 14A | Preliminary proxy statement | Aug 1, 2018 | Sep 24, 2018 |
| DEFA14A | Additional proxy material | Jul 18, 2017 | — |
| DEF 14A | Proxy statement | Jul 18, 2017 | Sep 7, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 6, 2017 | Jul 6, 2017 |
| DEFA14A | Additional proxy material | Aug 8, 2016 | — |
| DEFA14A | Additional proxy material | Jul 6, 2016 | — |
| DEF 14A | Proxy statement | Jul 6, 2016 | Aug 25, 2016 |
| PRE 14A | Preliminary proxy statement | Jun 2, 2016 | Jun 2, 2016 |
| DEFA14A | Additional proxy material | Apr 13, 2015 | — |
| DEF 14A | Proxy statement | Apr 13, 2015 | May 15, 2015 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2015 | Mar 23, 2015 |
| DEFA14A | Additional proxy material | May 12, 2014 | — |
| DEF 14A | Proxy statement | May 12, 2014 | Jun 10, 2014 |
| DEFA14A | Additional proxy material | Sep 24, 2013 | — |
| DEF 14A | Proxy statement | Sep 24, 2013 | Oct 22, 2013 |
| DEFA14A | Additional proxy material | Sep 11, 2012 | — |
| DEF 14A | Proxy statement | Sep 11, 2012 | Oct 5, 2012 |
| PRE 14A | Preliminary proxy statement | Aug 31, 2012 | Oct 5, 2012 |
| DEF 14A | Proxy statement | Jan 4, 2012 | Feb 15, 2012 |
| PRE 14A | Preliminary proxy statement | Dec 21, 2011 | Dec 20, 2011 |
| DEFA14A | Additional proxy material | Jun 20, 2011 | — |
| DEF 14A | Proxy statement | Jun 20, 2011 | Jul 19, 2011 |
| DEF 14A | Proxy statement | Sep 29, 2010 | Nov 2, 2010 |
| DEF 14A | Proxy statement | Nov 20, 2009 | Sep 30, 2009 |
| PRE 14A | Preliminary proxy statement | Nov 13, 2009 | Sep 30, 2009 |
| DEF 14A | Proxy statement | Apr 29, 2008 | Jun 3, 2008 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2008 | Jun 3, 2008 |
| DEF 14A | Proxy statement | Oct 9, 2007 | Nov 2, 2007 |
| DEF 14C | Information statement | Apr 3, 2007 | Mar 26, 2007 |
| PRE 14C | Filing | Mar 22, 2007 | Mar 26, 2006 |
| DEF 14C | Information statement | Sep 20, 2005 | Sep 20, 2005 |
| PRE 14C | Preliminary information statement schedule 14c | Sep 8, 2005 | Sep 8, 2005 |
| DEF 14A | Proxy statement | Apr 30, 2002 | Jun 12, 2002 |
| DEF 14A | Proxy statement | Apr 6, 2001 | May 8, 2001 |
| PRE 14A | Preliminary proxy statement | Mar 20, 2001 | May 8, 2001 |
| DEF 14A | Proxy statement | Apr 5, 2000 | May 9, 2000 |
| DEF 14A | Proxy statement | Dec 13, 1999 | Jan 20, 2000 |
| PRE 14A | Preliminary proxy statement | Nov 18, 1999 | Jan 20, 2000 |
| DEF 14A | Proxy statement | May 28, 1999 | Jun 29, 1999 |
| PRE 14A | Preliminary proxy statement | May 11, 1999 | Jun 29, 1999 |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TOVX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 894158
- Former names
- Synthetic Biologics, Inc. (until Oct 12, 2022); ADEONA PHARMACEUTICALS, INC. (until Feb 17, 2012); PIPEX PHARMACEUTICALS, INC. (until Oct 16, 2008); SHEFFIELD PHARMACEUTICALS INC (until Dec 8, 2006); SHEFFIELD MEDICAL TECHNOLOGIES INC (until May 14, 1997)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.